Abstract | AIM: The response with intravenous chemotherapy using cisplatin and paclitaxel in patients with advanced ovarian cancer is often substantial. However, this regression of the malignancy is not durable, and a majority of patients succumb to this disease process. It is possible that alternative types of chemotherapy and alternative routes of chemotherapy administration can improve the results of treatment and perhaps, reduce the morbidity and mortality that patients experience. METHODS: RESULTS: An important addition to perioperative chemotherapy delivery is the simultaneous use of heat with intraperitoneal drug delivery after a complete cytoreductive surgery. Drugs to be considered for HIPEC are cisplatin, gemcitabine, and melphalan. For EPIC, chemotherapy agents to consider include paclitaxel, pemetrexed, gemcitabine, and liposomal doxorubicin. For NIPEC, paclitaxel is the drug of choice usually combined with a systemic agent as bidirectional chemotherapy. Also, pemetrexed, gemcitabine, and liposomal doxorubicin are drugs to be considered for NIPEC in phase I/II trials. CONCLUSIONS:
|
Authors | Paul H Sugarbaker |
Journal | The journal of obstetrics and gynaecology research
(J Obstet Gynaecol Res)
Vol. 48
Issue 6
Pg. 1306-1317
(Jun 2022)
ISSN: 1447-0756 [Electronic] Australia |
PMID | 35343033
(Publication Type: Journal Article, Review)
|
Copyright | © 2022 Japan Society of Obstetrics and Gynecology. |
Chemical References |
- Pemetrexed
- Paclitaxel
- Cisplatin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Ovarian Epithelial
(drug therapy)
- Cisplatin
(therapeutic use)
- Cytoreduction Surgical Procedures
- Female
- Humans
- Hyperthermia, Induced
- Neoplasm Recurrence, Local
(drug therapy)
- Ovarian Neoplasms
(drug therapy, pathology, surgery)
- Paclitaxel
(therapeutic use)
- Pemetrexed
(therapeutic use)
- Peritoneal Neoplasms
(pathology)
|